Key result
High loading doses of rosuvastatin (40 mg) or atorvastatin (80 mg) before percutaneous coronary intervention significantly reduced the incidence of contrast-induced nephropathy compared to control.
Why the study?
Conflicting findings from available comparative trials have made it difficult to determine the best strategy for CI-AKI prevention in clinical practice.
Does a high loading dose of rosuvastatin or atorvastatin prevent contrast-induced acute kidney injury in patients undergoing PCI?
Observational (n=237)
Yes
Does a high loading dose of rosuvastatin or atorvastatin prevent contrast-induced acute kidney injury in patients undergoing PCI?
High loading doses of rosuvastatin or atorvastatin prior to PCI may reduce the incidence of contrast-induced acute kidney injury compared to no high-dose statin.
May support atorvastatin for CI-AKI prevention post-PCI; leaves open comparative efficacy versus rosuvastatin in randomized trials.
No takes yet. Share an insight, caveat, or question.
Sadawi et al. (2019) conducted an observational in Contrast-induced acute kidney injury (CI-AKI) (n=237). Rosuvastatin and Atorvastatin vs. No high loading dose of statins was evaluated on Contrast-induced nephropathy (CIN). High loading doses of rosuvastatin (40 mg) or atorvastatin (80 mg) before percutaneous coronary intervention significantly reduced the incidence of contrast-induced nephropathy compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: